View ValuationPolyPeptide Group 향후 성장Future 기준 점검 4/6PolyPeptide Group (는) 각각 연간 58.7% 및 14.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 58.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 13% 로 예상됩니다.핵심 정보58.7%이익 성장률58.60%EPS 성장률Life Sciences 이익 성장57.0%매출 성장률14.9%향후 자기자본이익률12.96%애널리스트 커버리지Low마지막 업데이트08 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Mar 31Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 5.3% to CHF27.31. The fair value is estimated to be CHF22.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making.공시 • Mar 18PolyPeptide Group AG, Annual General Meeting, Apr 08, 2026PolyPeptide Group AG, Annual General Meeting, Apr 08, 2026, at 16:00 W. Europe Standard Time.Reported Earnings • Mar 14Full year 2025 earnings released: €0.64 loss per share (vs €0.59 loss in FY 2024)Full year 2025 results: €0.64 loss per share (further deteriorated from €0.59 loss in FY 2024). Revenue: €391.9m (up 16% from FY 2024). Net loss: €21.2m (loss widened 8.2% from FY 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.Buy Or Sell Opportunity • Jan 19Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to CHF29.73. The fair value is estimated to be CHF24.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.7% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 18% in a year. Earnings are forecast to grow by 92% in the next year.공시 • Dec 05+ 1 more updatePolyPeptide Group AG to Report Fiscal Year 2026 Results on Mar 09, 2027PolyPeptide Group AG announced that they will report fiscal year 2026 results on Mar 09, 2027공시 • Sep 23PolyPeptide Group AG Achieves Significant Milestone in Malmo Expansion ProjectPolyPeptide Group AG announced the successful delivery and installation of pre-built modules at its Malmo, Sweden facility. This marks a key milestone in the company's modular expansion project at the site, which aims to double its solid-phase peptide synthesis (SPPS) capacity. The expansion, first announced in January 2025, is a central component of PolyPeptide's mid-term strategy to meet rising global demand for peptide production. The EUR 100 million metabolic program investment was largely funded by a large pharmaceutical partner and will create around 100 permanent new positions. It is anticipated that the expansion will be significantly faster than previous engineering projects due to the modular construction approach. Following installation, the modules will now undergo mechanical completion and automation, followed by qualification and commissioning. Key Project Highlights: Accelerated timeline: The Malmo capacity expansion is on track to be faster than previous engineering expansions due to the modular approach. Strategic partnership: The EUR 100 million investment was largely funded by a largest pharmaceutical player. Modular construction: Pre-built manufacturing modules installed with proprietary manufacturing systems, delivered and installed on-site. Operational continuity: Existing manufacturing operations remain uninterrupted. Advanced technology: Integrated engineering, automation, and process control. Quality assurance: All modules built to meet stringent pharmaceutical GMP standards. The additional capacity will primarily support one of PolyPeptide's large commercial agreements, contributing to its long-term growth initiatives and capital deployment strategy. As communicated in its mid-term outlook, the company expects over the mid-term horizon and on average, capital expenditures of 15-20% of revenue to ensure capacity beyond 2028.Reported Earnings • Aug 14First half 2025 earnings released: €0.80 loss per share (vs €0.35 loss in 1H 2024)First half 2025 results: €0.80 loss per share (further deteriorated from €0.35 loss in 1H 2024). Revenue: €167.1m (up 24% from 1H 2024). Net loss: €26.5m (loss widened 133% from 1H 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.New Risk • Aug 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.공시 • Apr 11Polypeptide Group Ag Appoints Jo Lecouilliard as Independent DirectorPolyPeptide Group AG announced the appointment of Jo LeCouilliard as Independent Director.Buy Or Sell Opportunity • Apr 07Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 52% to CHF14.27. The fair value is estimated to be CHF17.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Meanwhile, the company became loss making.New Risk • Mar 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (7.8% average weekly change).Buy Or Sell Opportunity • Jan 23Now 24% overvaluedOver the last 90 days, the stock has fallen 4.9% to CHF27.25. The fair value is estimated to be CHF21.98, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 18% in a year. Earnings are forecast to grow by 95% in the next year.New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Dec 16Now 29% overvaluedOver the last 90 days, the stock has fallen 8.5% to CHF29.70. The fair value is estimated to be CHF23.11, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Nov 25Now 21% overvaluedOver the last 90 days, the stock has fallen 19% to CHF27.70. The fair value is estimated to be CHF22.88, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making.New Risk • Aug 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Buy Or Sell Opportunity • Apr 02Now 23% undervaluedOver the last 90 days, the stock has risen 63% to CHF28.55. The fair value is estimated to be CHF36.86, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 8.8% in a year. Earnings are forecast to grow by 77% in the next year.Reported Earnings • Mar 14Full year 2023 earnings released: €1.56 loss per share (vs €0.23 profit in FY 2022)Full year 2023 results: €1.56 loss per share (down from €0.23 profit in FY 2022). Revenue: €324.9m (up 16% from FY 2022). Net loss: €51.4m (down €59.2m from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom.공시 • Dec 19PolyPeptide Group AG, Annual General Meeting, Apr 09, 2025PolyPeptide Group AG, Annual General Meeting, Apr 09, 2025.공시 • Dec 17+ 1 more updatePolyPeptide Group AG to Report First Half, 2025 Results on Aug 12, 2025PolyPeptide Group AG announced that they will report first half, 2025 results on Aug 12, 2025Reported Earnings • Aug 19First half 2023 earnings released: €1.04 loss per share (vs €0.31 profit in 1H 2022)First half 2023 results: €1.04 loss per share (down from €0.31 profit in 1H 2022). Revenue: €131.8m (down 1.4% from 1H 2022). Net loss: €34.3m (down 434% from profit in 1H 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in the United Kingdom.Board Change • Jul 26High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. Non-Executive Director Erik Schropp is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Feb 08+ 3 more updatesPolyPeptide Group AG to Report First Half, 2024 Results on Aug 13, 2024PolyPeptide Group AG announced that they will report first half, 2024 results on Aug 13, 2024이익 및 매출 성장 예측LSE:0AAJ - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202863869-1991412/31/202755041-3974412/31/202648017-4935312/31/2025389-21-3178N/A9/30/2025379-280108N/A6/30/2025369-3532139N/A3/31/2025353-2717114N/A12/31/2024337-20289N/A9/30/2024330-241687N/A6/30/2024324-293085N/A3/31/2024322-40561N/A12/31/2023320-51-2036N/A9/30/2023300-44-621N/A6/30/2023279-37-104-35N/A3/31/2023280-14-89-15N/A12/31/20222818-735N/A9/30/202228120-747N/A6/30/202228133-759N/A3/31/202228140-4833N/A12/31/202128247-2057N/A9/30/202127748-467N/A6/30/2021271481377N/A3/31/2021248401063N/A12/31/202022431649N/A12/31/2019203263656N/A12/31/201818124N/A23N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 0AAJ 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(3.4%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: 0AAJ (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: 0AAJ 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: 0AAJ 의 수익(연간 14.9%)이 UK 시장(연간 4.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 0AAJ 의 수익(연간 14.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 0AAJ의 자본 수익률은 3년 후 13%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 14:50종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스PolyPeptide Group AG는 11명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Charles PitmanBarclaysEstelle BétriseyBerenbergPatrick Andrew WoodBofA Global Research8명의 분석가 더 보기
New Risk • Apr 01New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Mar 31Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 5.3% to CHF27.31. The fair value is estimated to be CHF22.41, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making.
공시 • Mar 18PolyPeptide Group AG, Annual General Meeting, Apr 08, 2026PolyPeptide Group AG, Annual General Meeting, Apr 08, 2026, at 16:00 W. Europe Standard Time.
Reported Earnings • Mar 14Full year 2025 earnings released: €0.64 loss per share (vs €0.59 loss in FY 2024)Full year 2025 results: €0.64 loss per share (further deteriorated from €0.59 loss in FY 2024). Revenue: €391.9m (up 16% from FY 2024). Net loss: €21.2m (loss widened 8.2% from FY 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
Buy Or Sell Opportunity • Jan 19Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 27% to CHF29.73. The fair value is estimated to be CHF24.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.7% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 18% in a year. Earnings are forecast to grow by 92% in the next year.
공시 • Dec 05+ 1 more updatePolyPeptide Group AG to Report Fiscal Year 2026 Results on Mar 09, 2027PolyPeptide Group AG announced that they will report fiscal year 2026 results on Mar 09, 2027
공시 • Sep 23PolyPeptide Group AG Achieves Significant Milestone in Malmo Expansion ProjectPolyPeptide Group AG announced the successful delivery and installation of pre-built modules at its Malmo, Sweden facility. This marks a key milestone in the company's modular expansion project at the site, which aims to double its solid-phase peptide synthesis (SPPS) capacity. The expansion, first announced in January 2025, is a central component of PolyPeptide's mid-term strategy to meet rising global demand for peptide production. The EUR 100 million metabolic program investment was largely funded by a large pharmaceutical partner and will create around 100 permanent new positions. It is anticipated that the expansion will be significantly faster than previous engineering projects due to the modular construction approach. Following installation, the modules will now undergo mechanical completion and automation, followed by qualification and commissioning. Key Project Highlights: Accelerated timeline: The Malmo capacity expansion is on track to be faster than previous engineering expansions due to the modular approach. Strategic partnership: The EUR 100 million investment was largely funded by a largest pharmaceutical player. Modular construction: Pre-built manufacturing modules installed with proprietary manufacturing systems, delivered and installed on-site. Operational continuity: Existing manufacturing operations remain uninterrupted. Advanced technology: Integrated engineering, automation, and process control. Quality assurance: All modules built to meet stringent pharmaceutical GMP standards. The additional capacity will primarily support one of PolyPeptide's large commercial agreements, contributing to its long-term growth initiatives and capital deployment strategy. As communicated in its mid-term outlook, the company expects over the mid-term horizon and on average, capital expenditures of 15-20% of revenue to ensure capacity beyond 2028.
Reported Earnings • Aug 14First half 2025 earnings released: €0.80 loss per share (vs €0.35 loss in 1H 2024)First half 2025 results: €0.80 loss per share (further deteriorated from €0.35 loss in 1H 2024). Revenue: €167.1m (up 24% from 1H 2024). Net loss: €26.5m (loss widened 133% from 1H 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
New Risk • Aug 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
공시 • Apr 11Polypeptide Group Ag Appoints Jo Lecouilliard as Independent DirectorPolyPeptide Group AG announced the appointment of Jo LeCouilliard as Independent Director.
Buy Or Sell Opportunity • Apr 07Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 52% to CHF14.27. The fair value is estimated to be CHF17.84, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.1% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Mar 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (7.8% average weekly change).
Buy Or Sell Opportunity • Jan 23Now 24% overvaluedOver the last 90 days, the stock has fallen 4.9% to CHF27.25. The fair value is estimated to be CHF21.98, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 18% in a year. Earnings are forecast to grow by 95% in the next year.
New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Dec 16Now 29% overvaluedOver the last 90 days, the stock has fallen 8.5% to CHF29.70. The fair value is estimated to be CHF23.11, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Nov 25Now 21% overvaluedOver the last 90 days, the stock has fallen 19% to CHF27.70. The fair value is estimated to be CHF22.88, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.7% over the last 3 years. Meanwhile, the company became loss making.
New Risk • Aug 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Buy Or Sell Opportunity • Apr 02Now 23% undervaluedOver the last 90 days, the stock has risen 63% to CHF28.55. The fair value is estimated to be CHF36.86, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.0% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 8.8% in a year. Earnings are forecast to grow by 77% in the next year.
Reported Earnings • Mar 14Full year 2023 earnings released: €1.56 loss per share (vs €0.23 profit in FY 2022)Full year 2023 results: €1.56 loss per share (down from €0.23 profit in FY 2022). Revenue: €324.9m (up 16% from FY 2022). Net loss: €51.4m (down €59.2m from profit in FY 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Life Sciences industry in the United Kingdom.
공시 • Dec 19PolyPeptide Group AG, Annual General Meeting, Apr 09, 2025PolyPeptide Group AG, Annual General Meeting, Apr 09, 2025.
공시 • Dec 17+ 1 more updatePolyPeptide Group AG to Report First Half, 2025 Results on Aug 12, 2025PolyPeptide Group AG announced that they will report first half, 2025 results on Aug 12, 2025
Reported Earnings • Aug 19First half 2023 earnings released: €1.04 loss per share (vs €0.31 profit in 1H 2022)First half 2023 results: €1.04 loss per share (down from €0.31 profit in 1H 2022). Revenue: €131.8m (down 1.4% from 1H 2022). Net loss: €34.3m (down 434% from profit in 1H 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Life Sciences industry in the United Kingdom.
Board Change • Jul 26High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. Non-Executive Director Erik Schropp is the most experienced director on the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Feb 08+ 3 more updatesPolyPeptide Group AG to Report First Half, 2024 Results on Aug 13, 2024PolyPeptide Group AG announced that they will report first half, 2024 results on Aug 13, 2024